Close

Drug Research

Capsule-in-Capsule Systems Expanding Oral Dosage Design

The pharmaceutical sector has witnessed a growing demand for more sophisticated drug delivery systems that can address the complexities of modern therapeutics. One of the most innovative approaches to meeting this challenge is the development of nested capsule technologies....

Regulatory Intelligence Supporting Accelerated Drug Development

The global pharmaceutical environment is becoming increasingly complex, with regulatory agencies frequently updating guidelines to keep pace with scientific advancements and emerging health threats. In this context, the role of regulatory intelligence supporting accelerated drug development has never been...

Predictive Formulation Design in Oral Solid Dose Development

The integration of computational modeling and algorithmic analysis is currently redefining the methodology behind tablet and capsule creation in the pharmaceutical sector. Pharmaceutical organizations are increasingly transitioning away from empirical trial and error approaches in favor of data driven...

Bristol Myers Squibb Expands Strategic AI Partnership with Schrödinger

Bristol Myers Squibb has expanded its ongoing strategic partnership with Schrödinger through a new agreement to deploy the agentic AI co-scientist platform, Bunsen, across its research operations. Building upon an established collaboration in which Bristol Myers Squibb already utilizes...

Immediate Release Technologies Advancing Oral Drug Performance

The pharmaceutical industry is experiencing a significant shift in the development of fast acting oral medications, driven by the need for rapid onset of action and improved patient adherence. The optimization of drug release profiles is fundamental to therapeutic...

GLP-1 Therapies Broadening Clinical Treatment Pathways

The pharmaceutical industry is currently witnessing a significant expansion in the clinical utility of glucagon-like peptide 1 receptor agonists, moving well beyond their initial applications in type 2 diabetes and obesity management. As more data from large-scale cardiovascular and...

Combination Therapeutics Strengthening GLP-1 Treatment

The pharmaceutical sector is currently undergoing a significant transition from monotherapy to multi-receptor targeting in the management of metabolic disorders. While single-agent glucagon-like peptide 1 receptor agonists have provided a fundamental foundation for treating type 2 diabetes and obesity,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »